



PILLAR***ASPIRE**

*RGT criteria in SMV arms; end treatment at Week 24 if HCV RNA <25 IU/mL detectable/undetectable at Week 4 and <25 IU/mL undetectable at Weeks 12, 18 and 20 (all other patients continued PegIFN/RBV up to Week 48).

SMV, simeprevir; QD, once-daily; PegIFN/RBV, peginterferon- α and ribavirin; FU, follow-up; HCV, hepatitis C virus.